drugset / Trial / NCT05123599

A Study of JNJ-73763989, JNJ-64300535, and Nucleos(t)Ide Analogs in Virologically Suppressed, Hepatitis B e Antigen (HBeAg)- Negative Participants With Chronic Hepatitis B Virus Infection

NCT05123599

Phase 1 Completed 24 enrolled Janssen Research & Development, LLC
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the efficacy of the study intervention based on hepatitis B surface antigen (HBsAg) levels.

Timeline

Start
2021-12-06
Primary completion
2023-07-31
Completion
2024-06-26

Drugs

EvaluationDrugModalityDoseRoute
Subject JNJ-64300535 Vaccine Intramuscular
Subject JNJ-73763989 Small interfering RNA (siRNA) Subcutaneous
Background ETV monohydrate Unknown Oral
Background TAF Unknown Oral
Background Tenofovir disoproxil fumarate Small molecule Oral